GlassScriptPhysician profile
Marc D London
NPI 1720140767
$30,961.02
in general payments reported to CMS, 2019-2025
68 companies · $2,680 in 2025
The $2,680 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,370 · 2020: $8,787 · 2021: $7,184 · 2022: $4,343 · 2023: $2,719 · 2024: $2,879 · 2025: $2,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,276 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,275.51 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,078.68 | 2021-2025 | |
| Allergan, INC. | $8,422.04 | 2019-2022 | |
| Ucb, INC. | $934.86 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Lilly USA, LLC | $910.51 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Kyowa Kirin, INC. | $734.42 | 2019-2025 | Nourianz |
| Pfizer INC. | $617.41 | 2019-2025 | |
| Eisai INC. | $603.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $523.10 | 2019-2024 | |
| Sk Life Science, INC. | $479.55 | 2020-2025 | Xcopri |
| Amgen INC. | $476.42 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $441.67 | 2019-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $389.94 | 2019-2025 | Rytary, Crexont |
| Genzyme Corporation | $337.36 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $336.20 | 2023-2024 | Aptiom |
| Lundbeck LLC | $332.01 | 2020-2025 | Vyepti, Rexulti |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc London listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.